First Merchants Corp
Change company Symbol lookup
Select an option...
FRME First Merchants Corp
SFDMY Shanghai Fudan Microelectronics Group Co Ltd
NWL Newell Brands Inc
MRK Merck & Co Inc
FWONA Liberty Media Corp
RSG Republic Services Inc
TENB Tenable Holdings Inc
NLSN Nielsen Holdings PLC
CLAR Clarus Corp
SBSW Sibanye Stillwater Ltd
Go

Financials : Banks | Small Cap Value
Company profile

First Merchants Corporation is a financial holding company. The Company has a bank charter, First Merchants Bank (the Bank), which is opened for business in Muncie, Indiana. The Bank also operates First Merchants Private Wealth Advisors (a division of First Merchants Bank). The Bank includes approximately 109 banking locations in Indiana, Ohio, Michigan and Illinois. In addition to its branch network, the Company offers comprehensive electronic and mobile delivery channels to its customers. The Company operates in a single business segment, which is community banking. Through the Bank, the Company offers a range of financial services, including accepting time, savings and demand deposits; making consumer, commercial, agri-business and real estate mortgage loans; providing personal and corporate trust services; offering full-service brokerage and private wealth management; and providing letters of credit, repurchase agreements and other corporate services.

Closing Price
$40.59
Day's Change
-2.13 (-4.99%)
Bid
--
Ask
--
B/A Size
--
Day's High
42.16
Day's Low
39.83
Volume
(Average)
Volume:
161,205

10-day average volume:
156,005
161,205

Skye Bioscience Announces THCVHS Late-Breaking Preclinical Abstracts Selected by American Association of Pharmaceutical Scientists Meeting PharmSci 360

9:00 am ET September 21, 2021 (Globe Newswire) Print

Skye Bioscience, Inc. (OTCQB: SKYE) ("Skye"), a biopharmaceutical company developing proprietary cannabinoid-derived molecules to treat diseases with significant unmet need, announced today its research partner, the University of Mississippi will present late-breaking preclinical data evaluating different nanoemulsion formulations of its prodrug of tetrahydrocannabinol (THC), THCVHS, in addition to the superiority of THCVHS, in lowering intraocular pressure in dutch belted rabbits when co-administered with netarsudil, a rho-kinase inhibitor, at the 2021 American Association of Pharmaceutical Scientists Meeting (AAPS) PharmSci 360 being held October 17 -20, 2021, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Details of late-breaking poster presentations:

Title: IOP Profile in Dutch Belted Rabbits Following Topical Application of D9-Tetrahydrocannabinol-Valine-Hemisuccinate (THC-VHS, NB1111) Nanoemulsion Formulations

Poster number: M0930-06-33

Date: Monday, October 18, 2021 at 9:30AM - 10:30AM ET

Title: Co-administration of D9-Tetrahydrocannabinol-Valine-Hemisuccinate (THC-VHS, NB1111) and Netarsudil, a Rho-Kinase Inhibitor, Produces Superior IOP Lowering Activity in Dutch Belted Rabbits

Poster number: T0930-06-33

Date: Tuesday, October 19, 2021 at 9:30AM - 10:30AM ET

Full abstracts are available online at www.aaps.org. Posters will be available on Skye's website following the presentations.

About the University of Mississippi

The University of Mississippi, the state's flagship university, is among the elite group of R-1: Doctoral Universities - Highest Research Activity in the Carnegie Classification. The university has a long history of producing leaders in public service, academics, research, and business. Its 15 academic divisions include a major medical school, nationally recognized schools of accountancy, law and pharmacy, and an honors college acclaimed for a blend of academic rigor, experiential learning, and opportunities for community action. Over 50 years ago, the university was awarded the first federal government contract to cultivate cannabis for research.

About Skye Bioscience

Skye Bioscience Inc. is a biopharmaceutical company unlocking the pharmaceutical potential of cannabinoids through the development of its proprietary cannabinoid-derived molecules to treat diseases with significant unmet needs. The company's lead program, THCVHS, is focused on treating glaucoma, the world's leading cause of irreversible blindness. For more information, please visit: www.skyebioscience.com.

CONTACT

Karam Takhar

VP, Corporate Development & Investor Relations

Email: ir@skyebioscience.com

Phone: (858) 410-0266

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements regarding our product development, business strategy, timing of clinical trials and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "plans," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye's most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.

https://ml.globenewswire.com/media/c450c065-840d-4173-a5c3-5718c201753f/small/skye-logo-dark-blue-png.png

https://ml.globenewswire.com/media/c450c065-840d-4173-a5c3-5718c201753f/small/skye-logo-dark-blue-png.png

comtex tracking

COMTEX_393733668/2010/2021-09-21T09:00:04

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.